TPBG
CORT icon

Turning Point Benefit Group’s Corcept Therapeutics CORT Stock Holding History

Turning Point Benefit Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3
Closed -$104 – 242
2025
Q4 		$104 Hold
3
– – ﹤0.01% 804
2025
Q3 		$252 Buy
+3
New +$217 ﹤0.01% 621

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Turning Point Benefit Group's CORT Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 3 shares — an estimated $104 sold.

Turning Point Benefit Group first reported a position in CORT in Q3 2025 and held it in 2 quarters. The position peaked at $252 in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 3 Corcept Therapeutics shares in Q1 2026, an estimated $104.
  • Turning Point Benefit Group first reported a position in Corcept Therapeutics in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Corcept Therapeutics position peaked at $252 in Q3 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.